This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act
of 1934, including expectations regarding our aspiration to become a leading biotech company and the planned achievement of our “Alnylam P5x25” strategy, our ability
to attain financial self-sustainability, our preliminary fourth quarter and 2021 fiscal year global net product revenue and patients on therapy, the probability of success of
our RNAi therapeutics platform, the drivers of our future growth potential, including the potential of our TTR franchise, our continued confidence in the design and
ongoing execution of the APOLLO-B Phase 3 study and the evidence for investigational RNAi therapeutics in ATTR cardiomyopathy, the potential opportunity for RNAi
therapeutics in prevalent diseases, and the potential of our engine for sustainable innovation including the potential for improved product profiles to emerge from our
IKARIA and GEMINI platforms, as well as the achievement of additional pipeline and regulatory milestones. Actual results and future plans may differ materially from
those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation: the direct or
indirect impact of the COVID-19 global pandemic or any future pandemic on our business, results of operations and financial condition and the effectiveness or
timeliness of our efforts to mitigate the impact of the pandemic; the potential impact of the recent leadership transition on our ability to attract and retain talent and to
successfully execute on our “Alnylam P5x25” strategy; the finalization and audit of our fourth quarter and 2021 fiscal year financial results which could potentially result
in changes or adjustments to the selected preliminary financial results presented herein;
相关推荐
热门下载
推荐
快速链接
热门标签
关注我们
扫码关注我们
了解更多相关信息